Form 4: Zimmer Biomet CHRO Earns Performance RSUs

Zimmer Biomet Holdings' SVP and CHRO, Lori Winkler, earned 3,935 performance-based Restricted Stock Units following the achievement of 2023-2025 performance targets.

Summary

• Lori Winkler, SVP and CHRO of Zimmer Biomet Holdings, Inc. (ZBH), earned 3,935 performance-based Restricted Stock Units (RSUs).
• These RSUs were initially granted on March 6, 2023, with the number earned contingent on meeting specific performance conditions over the 2023-2025 period.
• The determination that 3,935 RSUs were earned was made on February 19, 2026, based on the actual performance achieved.
• Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.
• The earned RSUs are scheduled to vest on March 6, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive indicator, as it confirms the achievement of performance targets for the 2023-2025 period, which is generally a good sign for company operations and executive alignment.

Positives

• Lori Winkler earned 3,935 performance-based RSUs, indicating the successful achievement of specific company performance conditions for the 2023-2025 period.
• The upcoming vesting of these RSUs on March 6, 2026, will increase the executive's direct ownership in the company, aligning interests with shareholders.

Risks

• The ultimate value of the earned RSUs, once vested and converted to common stock, is subject to the future market price fluctuations of Zimmer Biomet Holdings, Inc. common stock.

Future Outlook

The earned RSUs are scheduled to vest on March 6, 2026, at which point they will convert into shares of Zimmer Biomet common stock, increasing the executive's direct equity ownership.

Management Comments

• The reporting person was granted performance-based RSUs, with the number earned determined by meeting specific performance conditions over a 2023-2025 period.

Industry Context

StockSavvy.ai notes that performance-based RSU grants are a common and effective executive compensation practice in the medical device industry. This type of compensation aligns executive incentives with long-term company performance and shareholder value, and this filing indicates successful achievement of internal targets for Zimmer Biomet.

Comparison to Industry Standards

• Performance-based RSU grants are a standard component of executive compensation packages across the medical technology sector, including peers such as Stryker Corporation, Medtronic plc, and Johnson & Johnson MedTech.
• The structure, which ties vesting to multi-year performance metrics (2023-2025), is consistent with best practices aimed at fostering long-term strategic alignment and sustainable growth, rather than short-term gains.
• The specific number of RSUs earned (3,935) is relative to the executive's role and the company's overall compensation philosophy, which is generally benchmarked against similar-sized companies in the S&P 500 and the broader medical device industry.

Stakeholder Impact

• Shareholders: This transaction indicates that management's incentives are aligned with long-term performance, as the RSUs were earned based on achieving specific company targets. Increased executive ownership can signal confidence in the company's future.
• Employees: Reflects the company's established compensation structure for executives, which may influence broader employee incentive programs and morale.

Next Steps

• The 3,935 earned RSUs will vest on March 6, 2026, at which point they will convert into shares of Zimmer Biomet common stock.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event where performance-based Restricted Stock Units were earned. While it indicates the company met its performance targets for the 2023-2025 period, which is a positive operational sign, it does not present new information significant enough to warrant a change in investment recommendation. It primarily confirms previously established compensation plans and performance achievements.

Keywords

Zimmer Biomet, ZBH, Restricted Stock Units, RSU, executive compensation, insider transaction, performance-based, stock grant, Form 4